Cognos Therapeutics is an Inglewood, California medical device company developing SINNAIS, an implantable smart pump that delivers drugs directly into the brain's ventricles through the cerebrospinal fluid. The device pairs a piezoelectric micropump capable of one-microliter dosing with optical sensors and microdialysis that read CSF biomarkers such as beta-amyloid and tau, and transmits results wirelessly to a physician's tablet for remote monitoring and reprogramming. Intended applications include brain and spinal tumors, CAR-T cell therapy delivery, and neurodegenerative conditions such as Alzheimer's disease. The company is running a clinical and research collaboration with Massachusetts General Hospital and Harvard on delivering therapeutics to the brain via the device.